Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.

Primary Aim:

• To determine safety of stellate ganglion block (SGB) in ARDS

Secondary Aim:

• To determine efficacy of SGB in slowing the progression of ARDS

Inclusion Criteria:

• Subjects age 18 to 80
• Subjects with PCR documented diagnosis of COVID-19 ARDS requiring critical care and transfer to intensive care unit
• Bilateral opacities consistent with pulmonary edema must be present and may be detected on CT or chest radiograph

Exclusion Criteria:

• Subjects with pre-existing cardiac failure
• Hemodynamic Instability
• Subject on Extracorporeal membrane oxygenation (ECMO)
• Anatomical inability to do a stellate block